Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebotelimab (MGD013) Phase 1 in Advanced Solid Tumors
NCT03219268Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Aug 2017
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of tebotelimab in solid tumor (advanced stage) and hematologic neoplasms (12 arms), sponsored by MacroGenics. Primary endpoints: Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy) up to 24 months and Number of participants with Treatment-Emergent Adverse Events as assessed by CTCAE v4.03 (tebotelimab plus margetuximab) up to 24 months. Started Aug 2017; status: completed.
02
Drugs
tebotelimab
03
Conditions
solid tumor (advanced stage)hematologic neoplasms
Beyond the preview
Go deeper on NCT03219268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219268.